🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For FreeCopy Portfolio

Britain to spend £3.7 billion on vaccines and bear liability, watchdog says

Published 16/12/2020, 00:17
© Reuters. People get injections of Pfizer-BioNTech COVID-19 vaccine in Wolverhampton
PFE
-
JNJ
-
MRNA
-

LONDON (Reuters) - Britain has agreed to spend 3.7 billion pounds on COVID-19 vaccines and in most cases will bear the liability if claims are made against the pharmaceutical firms involved, the National Audit Office (NAO) said on Wednesday.

The government has agreed supply deals for 357 million doses of seven different candidate shots, but has not gone into detail about how much it has spent or indemnity agreements, citing commercial confidentiality around the contracts.

The NAO said the business ministry had signed firm deals for five of the candidates, including the Pfizer/BioNTech shot which has already been approved and is being rolled out, as well as those developed by Oxford/AstraZeneca, France's Valneva, Novavax and Moderna (NASDAQ:MRNA).

Britain also has deals in principle for Sanofi/GlaxoSmithKline's shot as well as Johnson & Johnson (NYSE:JNJ)'s candidate.

The government has invested in the development and clinical trials of some of the vaccines it has agreed supply deals for, and agreed to indemnify the firms against liability.

Those agreements mean that in four of the five finalised contracts, there was no cap on how much the government could pay if there is a successful claim against one of the companies, the report said.

The NAO said the business ministry agreed upfront payments of 914 million pounds on the five contracts it has signed, prior to regulatory approval of any of the vaccines.

Only one of the contracts provides for a full refund of the upfront payment if the vaccine fails to achieve regulatory approval.

The NAO noted that the government had worked "quickly and effectively" to secure vaccines, demonstrated when Britain became the first country in the world to deploy Pfizer (NYSE:PFE)'s vaccine last week.

"We have worked at a pace and scale never been done before to ensure the British public receive a vaccine that meets strict safety standards as quickly as possible," a spokeswoman for the business ministry said.

In all, the total cost of purchasing and deploying vaccines was uncertain, the NAO said, but estimated that it could cost up to 11.7 billion pounds.

© Reuters. People get injections of Pfizer-BioNTech COVID-19 vaccine in Wolverhampton

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.